| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Subunit of a Guanine Nucleotide Binding Protein, Gs, from Metastatic Variants of B16 Melanoma Cells1
Molecular and Environmental Toxicology Program, School of Pharmacy, University of Colorado, Boulder, Colorado 80309-0297 [C. A. L-C., K. A. D., A. M. M.], and Department of Laboratory Medicine and Pathology, Dight Laboratories, University of Minnesota, Minneapolis, Minnesota 55455 [B. R. L.]
The signal transducing regulatory protein (Gs
) was examined in B16 melanoma clones of low (F1C29) and high (F10C23) experimental metastatic potential. Incorporation of the photoaffinity analogue, [8-azido-
-32P]GTP, into Gs
was decreased in F10C23 extracts when compared to F1C29. This difference disappeared when the photolabeling reaction was carried out at an elevated temperature which enhanced the rate of GTP exchange, suggesting functional differences in the ability of Gs
to bind or release GTP rather than dissimilar intracellular Gs
concentrations. Differential Gs
photolabeling occurred only during the period of rapid growth when F10C23 cells proliferated faster than F1C29 cells. During the recovery phase of growth immediately following plating and at confluence, periods in which F1C29 and F10C23 growth rates are similar, Gs
photolabeling between the two clones was equal. CMT lung carcinoma clones of differential metastatic potential grew at a uniform rate at all stages of growth and also exhibited equal Gs
photolabeling. F10C23 cells were more responsive to
-melanocyte-stimulating hormone stimulation of adenylate cyclase activity than F1C29 cells at all growth stages. These results confirm previously observed functional differences in Gs
between B16 metastatic variants and show that photolabeling differences in Gs
are related to growth rate.
1 Supported by USPHS Grants ES02370 and HL37718; Research Career Development Award CA-00939 (to A. M. M.); American Cancer Society Grant IN-13-Z28; and a Leukemia Task Force grant (to B. R. L.).
2 To whom requests for reprints should be addressed.
Received 9/ 2/88. Revised 1/27/89. Accepted 3/17/89.
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |